Skip to content
Subscriber Only

Eisai Shares Fall Most In 6 Years on Alzheimer’s Drug Data

Eisai Co.’s shares dropped the most in more than six years after partner Biogen Idec Inc.’s experimental Alzheimer’s drug failed to show a statistically significant cognitive benefit for patients on a key dose.

The Japanese drugmaker’s shares traded 8.2 percent lower at 8,114 yen at 9:57 a.m. in Tokyo today, the biggest decline on an intraday basis since October 2008.